Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

CervoMed (CRVO) Shares Outstanding (Weighted Average) (2022 - 2025)

CervoMed (CRVO) has disclosed Shares Outstanding (Weighted Average) for 9 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) fell 67.82% to $2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2025, down 67.82% year-over-year, with the annual reading at $2.6 million for FY2025, 0.42% changed from the prior year.
  • Shares Outstanding (Weighted Average) hit $2.6 million in Q4 2025 for CervoMed, down from $9.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $9.0 million in Q3 2025 to a low of $88252.0 in Q2 2023.
  • Historically, Shares Outstanding (Weighted Average) has averaged $3.6 million across 4 years, with a median of $1.3 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): tumbled 95.67% in 2023 and later skyrocketed 8393.61% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $518140.0 in 2022, then decreased by 4.27% to $495995.0 in 2023, then surged by 1527.67% to $8.1 million in 2024, then plummeted by 67.82% to $2.6 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CRVO at $2.6 million in Q4 2025, $9.0 million in Q3 2025, and $8.8 million in Q2 2025.